Tata Memorial Centre asserts that its Rs 100 per tablet medication has the potential to prevent cancer recurrence. The tablet, developed by the institute, aims to not only prevent cancer from returning but also reduce treatment side effects by half. Currently awaiting approval from FSSAI, once sanctioned, the tablet is anticipated to be available in the market by June.
Trending
- Market Outlook: Nifty, Sensex Rebound Ahead of Key Earnings and Record IPO Week
- NSE to Build ₹380-Crore Cancer Care Facility at Tata Memorial Hospital’s ACTREC in Navi Mumbai
- Biggest IPO Week Ever: Over ₹30,000 Crore Fundraising Set to Hit Dalal Street Starting October 6
- Tata Capital IPO to Open October 6; Key Details and Subscription Guide
- Startup India Scheme: Empowering Innovation and Entrepreneurship in India
- MP Raja Ram Singh Seeks Government Action Against ‘Illegal Layoffs’ in TCS, IT Sector
- Sensex, Nifty End Higher as Metal and Banking Stocks Lead Recovery; Focus Shifts to Q2 Earnings, IPOs, and FOMC Minutes
- FPIs Pull Out ₹23,885 Crore from Indian Equities in September, Extending Sell-Off to Third Month
- Bitcoin Hits New All-Time High at $125,689 Amid US Government Shutdown and Market Rally
- Government Launches Probe into E-Commerce Platforms Over ‘Dark Pattern’ Fees
Ensuring Authenticity, Upholding Trust
